Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer
Milan Radovich(Caris Life Sciences (United States)), Kathy D. Miller(Indiana University Health)
Cited by 29
Related Papers
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells
|Oncogene|2005|305
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2021|255
A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer
|Breast Cancer Research|2018|69
A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas
|British Journal of Cancer|2016|63
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
|npj Breast Cancer|2017|59